c.tulloch

TL2 · Bochum

Contributes reviews on supplier material. Based in Bochum.

Joined 6 July 2025 · last posted 3d · groups: newcomer-guides

101 posts, newest first. Showing up to 150.

What a certificate commits its issuer to Replied, post #100 · Analytics › COA interpretation · 25 Jul 2026 · 0 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Coming back to: Payment method and the leverage it gives you, ranked Replied, post #25 · Sourcing › Payments · 23 Jul 2026 · 4 likes On post #23 — agreed on the reasoning, with one qualification. Recording the time from payment to dispatch is worth doing, because it is the part of the process most…
Deletion sequences: expected mass shifts by residue — the long version Replied, post #19 · Analytics › Impurities & related substances · 21 Jul 2026 · 0 likes Clear enough that I do not think I have a follow-up, which is unusual.
Reading order for a first week here, and what to skip until later — what changed since Replied, post #47 · Start Here › Welcome · 16 Jul 2026 · 0 likes Reading order would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still… Replied, post #42 · Compounds › Retatrutide · 11 Jul 2026 · 29 likes Speaking only to TRIUMPH as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the…
Pages past their review date, listed — does this still hold? Replied, post #46 · Meta › Wiki maintenance · 10 Jul 2026 · 0 likes Review dates: each maintained page has a review date (the date by which it should be checked). If a page is past its review date, flagging it here alerts the…
How much context is too much context in a first post? Replied, post #8 · Start Here › How to Ask · 4 Jul 2026 · 3 likes Context that matters: compound, how long in, current dose, relevant history. Context that does not matter: how you feel, your hopes for the outcome, your medical…
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #13 · Compounds › Repair & healing peptides · 4 Jul 2026 · 10 likes This is the sort of exchange that makes the archive worth searching.
About the Receptor biology category Replied, post #9 · Pharmacology › Receptor biology · 2 Jul 2026 · 2 likes Receptor occupancy required for a clinical effect is not the same as full occupancy, and dose-response curves flattening at the top is what you would expect from that.
Second pass at: When your prescriber and the evidence disagree Replied, post #43 · Clinical › Prescriber conversations · 30 Jun 2026 · 0 likes Prescription logistics: confirm whether it will be filled locally, requires mail order, or will be prescribed off-label and needs a compounding pharmacy. Different…
Does dual agonism explain the effect size, or is it dose? Replied, post #61 · Compounds › Tirzepatide · 26 Jun 2026 · 14 likes On post #57 — agreed on the reasoning, with one qualification. Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are…
Why we ask for units every single time, with three examples of what goes wrong Replied, post #38 · Start Here › How to Ask · 13 Jun 2026 · 0 likes If your question has a deadline — a parcel in transit, a delivery you have to accept or refuse — say so. People answer differently when there is a clock on it. Take the…
Reading a trial's population section before its results Replied, post #103 · Evidence › Trials · 9 Jun 2026 · 0 likes A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened…
Specificity, linearity, accuracy, precision, range, robustness — with real criteria Replied, post #27 · Analytics › Method validation · 8 Jun 2026 · 3 likes Where I part company with post #25, and it is a narrow parting. A method that reports the same number for every lot is worth a second look. Real processes vary, and a…
Racemisation and why it is invisible to a mass measurement Replied, post #3 · Analytics › Impurities & related substances · 8 Jun 2026 · 13 likes Narrowing the opening post, because the general version has more than one answer. On racemisation I would separate what is worth knowing from what is worth acting on.…
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #84 · Practice › Storage & stability · 7 Jun 2026 · 0 likes Post #82 describes the usual case. This is about the unusual one. I would be cautious about generalising from the reconstituted example above. It is a good example. It…
Peak-to-trough ratio at steady state for a weekly agent Replied, post #57 · Pharmacology › Pharmacokinetics · 3 Jun 2026 · 0 likes Peak-to-trough ratio: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like…
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #75 · Evidence › Journal club · 3 Jun 2026 · 0 likes Post #72 is the version of this I will quote in future. One addition. What I want from this indirect comparison thread is the list of things that would need to be true…
What a certificate commits its issuer to — the long version Replied, post #9 · Analytics › COA interpretation · 23 May 2026 · 11 likes This follows post #6 rather than contradicting it. Reading old certificates: if a certificate is dated years ago, the lot it describes might be old. That is not…
Request declined, with reasoning — what changed since Replied, post #38 · Meta › Feature requests · 11 May 2026 · 2 likes Reading rather than contributing, but this is the most useful thread I have found on it.
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #134 · Pharmacology › Pharmacokinetics · 8 May 2026 · 22 likes Worth separating two things that post #133 runs together. Washout would be much easier to settle if anyone reported the denominator. Almost nobody reports the…
I have no scientific background — can I still follow the analytics categories? Started this topic · Start Here › Welcome · 7 May 2026 · 7 likes The question in the title: I have no scientific background — can I still follow the analytics categories? I will give what I have already checked below so nobody…
Peak-to-trough ratio at steady state for a weekly agent — the long version Started this topic · Pharmacology › Pharmacokinetics · 6 May 2026 · 60 likes Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow…
Five questions in one post gets you one answer — how to split them Replied, post #71 · Start Here › How to Ask · 3 May 2026 · 0 likes "Has anyone had this happen" gets you anecdotes. "What would cause this, and what would distinguish the causes" gets you an explanation. The second question is almost…
Managing an unplanned gap in supply Replied, post #102 · Access › Shortages · 18 Apr 2026 · 1 like I read post #100 twice before replying, because I had assumed the opposite. Regional differences during a shortage are large, and a supply position in one country says…
Stability of BPC-157 in solution: what has been measured — one year on Replied, post #39 · Compounds › Repair & healing peptides · 18 Apr 2026 · 10 likes Answering the question post #37 raises rather than the one it answers. Oral versus injected administration claims for BPC-157: the preclinical work studied injection.…
Follow-up: State-level differences that actually matter Replied, post #49 · Regional › North America · 6 Apr 2026 · 22 likes I read post #45 twice before replying, because I had assumed the opposite. Cross-border purchasing raises both a legal question and a practical one, and the legal one…
Revisiting: Drawing up with one needle and injecting with another Replied, post #53 · Practice › Administration · 5 Apr 2026 · 4 likes Nothing in this subcategory is medical advice and none of it is a substitute for a demonstration from somebody qualified to give one, which most prescribers will do…
[2026 update] A report I filed that turned out to be wrong, and the correction Replied, post #11 · Sourcing › Vendor reports · 2 Apr 2026 · 9 likes Everything in post #9 holds. The case it does not cover is the one I have. Structured report format: compound, lot, independent testing service, method as reported,…
Grapefruit: why this class is not the class that cares Replied, post #88 · Practice › Interactions · 28 Mar 2026 · 21 likes The question underneath grapefruit is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it. Write down what you would…
The "under review" status pill and when a moderator applies it Replied, post #13 · Evidence › Preprints · 9 Mar 2026 · 0 likes Post #9 and I disagree about the size of the effect, not about the direction. Say it is a preprint in the first line rather than the last. Everything downstream depends…
An ABAB design with a data table and honest limitations — a second dataset Replied, post #25 · Research Methods › N-of-1 designs · 1 Mar 2026 · 0 likes Generalisability: a robust n-of-1 result applies to you. It does not tell you much about whether the effect generalises to others similar to you, much less to people…
[2026 update] What a good consultation looks like from the other side Replied, post #18 · Clinical › Prescriber conversations · 26 Feb 2026 · 0 likes One caution on good consultation: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
Why "dose equivalence" between different incretin analogues is a weak concept Replied, post #64 · Practice › Dosing & titration · 18 Feb 2026 · 2 likes There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which…
Second pass at: What "verified" means on our vendor pages, stated narrowly Replied, post #70 · Sourcing › Vendor reports · 15 Feb 2026 · 0 likes Do not adjust a reported figure. Post what the laboratory said and put your interpretation in a separate sentence. Posting it because the silence on this was starting…
Adducts: sodium, potassium, and the peak you did not expect — does this still hold? Replied, post #30 · Analytics › Mass spectrometry · 7 Feb 2026 · 28 likes The reason Adducts keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
Trifluoroacetate content and its consequences Replied, post #103 · Analytics › Impurities & related substances · 7 Feb 2026 · 19 likes The arithmetic in post #102 is right; the assumption feeding it is the part to check. Adding a null result on trifluoroacetate content. I looked, carefully, and found…
Second pass at: Metformin co-administration and additive GI effects Replied, post #45 · Practice › Interactions · 6 Feb 2026 · 0 likes Narrowing post #42, because the general version has more than one answer. Where a published interaction study exists it usually reports an area-under-curve ratio, and…
Common supplements people ask about, assessed one at a time — a second dataset Replied, post #42 · Practice › Interactions · 28 Jan 2026 · 19 likes Where I part company with post #38, and it is a narrow parting. Metformin: commonly co-administered and relevant to gastrointestinal tolerability. Gastrointestinal side…
Interpreting a result that disagrees with the supplier's certificate Replied, post #95 · Sourcing › Independent verification · 25 Jan 2026 · 5 likes Post #94 is right about the mechanism and I think understates the practical bit. My position on interpreting a result is current rather than settled. I have revised it…
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #61 · Clinical › Special populations · 24 Jan 2026 · 3 likes Coming back to post #57, because the follow-up matters more than the original answer. Medullary thyroid carcinoma history: an absolute contraindication because of the…
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #82 · Clinical › Special populations · 22 Jan 2026 · 9 likes Something worth flagging about older adults: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a…
Heterogeneity as information rather than as a nuisance Replied, post #72 · Evidence › Meta-analyses · 22 Jan 2026 · 19 likes That is a fair summary of where the discussion has got to.
A pen that felt like it delivered nothing: diagnosing it afterwards Replied, post #36 · Devices › Pens & autoinjectors · 4 Jan 2026 · 23 likes Nothing here is medical advice, and pen technique is the single easiest thing to have demonstrated in person rather than learned from a description. Caveat: everything…
Adsorption to container surfaces and to plastics Started this topic · Pharmacology › Formulation chemistry · 26 Dec 2025 · 37 likes On the subject in the title: Adsorption to container surfaces and to plastics Working notes rather than a conclusion. I was wrong about adsorption in a thread last…
Run-in periods and the population they select Replied, post #36 · Evidence › Trials · 16 Dec 2025 · 11 likes Adding the measurement that post #33 says would settle it. Entry criteria, run-in periods and the self-selection of people willing to enter a multi-year trial all…
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #93 · Compounds › Oral incretins · 15 Dec 2025 · 1 like Excipients are not inert from an analytical point of view. A certificate for a formulated tablet has to account for them, and one that reports a purity figure without…
Tracking a preprint to publication: a worked example Replied, post #82 · Evidence › Preprints · 8 Dec 2025 · 0 likes Building on post #79 rather than restating it. What would change my mind on tracking a preprint is a second dataset collected by someone with no stake in the first.…
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #64 · Compounds › Other compounds · 25 Nov 2025 · 0 likes On post #62 — agreed on the reasoning, with one qualification. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which…
Robustness: the parameters worth deliberately varying Replied, post #12 · Analytics › Method validation · 21 Nov 2025 · 0 likes Post #8 put the caveat in the right place and I want to underline it. For anyone finding this later: the short answer on robustness is that it depends on one thing, and…
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Replied, post #94 · Compounds › Tirzepatide · 17 Nov 2025 · 29 likes Tirzepatide titration schedules looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our…
[2026 update] What steady state means for the decision to escalate Replied, post #90 · Practice › Dosing & titration · 14 Nov 2025 · 3 likes A note on scope: what I am saying about steady state applies to the case in the first post and I would not extend it further without checking.
Reference intervals: how they are constructed and why one in twenty flags Replied, post #9 · Clinical › Bloodwork · 7 Nov 2025 · 17 likes That reframing is the whole thing. The facts I already had.
Payment mechanics and the recovery options that do not exist Replied, post #50 · Sourcing › Payments · 21 Oct 2025 · 19 likes Narrowing post #47, because the general version has more than one answer. The most useful thing anyone has posted about payment mechanics in this category was a table…
Second pass at: The mass-error checker and its intended scope Replied, post #41 · Data & Tools › Calculators · 18 Oct 2025 · 2 likes Sensible. I would want the same detail before I acted on it either.
Personal import allowances, compared — a second dataset Replied, post #9 · Access › International · 13 Oct 2025 · 0 likes Post #7 put the caveat in the right place and I want to underline it. A regional experience posted here should say which year it describes. The archive keeps these…
Waist circumference technique and its repeatability Replied, post #5 · Outcomes › Progress reports · 7 Oct 2025 · 23 likes Rate of change matters more than the absolute number for most of the questions people ask about their own series.
Micronutrient adequacy at low total intake — does this still hold? Replied, post #16 · Nutrition & Training › Protein & intake · 6 Oct 2025 · 12 likes Tracking intake for a week rather than permanently is usually enough to find out whether there is a problem. Permanent tracking has its own costs. One case, stated as…
Non-inferiority margins: how they are chosen and how they are abused Replied, post #3 · Evidence › Trials · 29 Sep 2025 · 30 likes Having read the whole non-inferiority margins thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a…
Titles that describe the question, not the situation — what changed since Replied, post #29 · Start Here › How to Ask · 20 Sep 2025 · 2 likes Seconded. It reads as careful rather than confident, which is the right register.
Follow-up: History of disordered eating and why it changes the conversation Replied, post #81 · Clinical › Special populations · 14 Sep 2025 · 4 likes Dedicated trials in under-studied populations are the only real remedy and several are ongoing, which is worth saying rather than speculating.
Can a home kit substitute for a laboratory report? A careful no Replied, post #8 · Analytics › Home & field testing · 8 Sep 2025 · 0 likes Answering the question post #4 raises rather than the one it answers. Weighing vials against declared fill is the most underrated home check available. It needs a…
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #25 · Evidence › Journal club · 17 Aug 2025 · 20 likes Source for the orforglipron phase 2 figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger…
High-resolution MS on aggregates and what it can see Replied, post #26 · Analytics › Mass spectrometry · 20 Jul 2025 · 20 likes I read post #24 twice before replying, because I had assumed the opposite. Quantitation by MS: most quantitation is done by LC-UV detection at 214 nm, not by MS,…
Hepatic steatosis: what the MASH trial evidence supports Replied, post #84 · Clinical › Comorbidities · 6 Jul 2025 · 21 likes Post #82 is right about the mechanism and I think understates the practical bit. A condition being an exclusion criterion in a trial does not mean the treatment is…
What a 2 ppm match establishes, and what it does not Replied, post #28 · Analytics › Mass spectrometry · 25 Jun 2025 · 1 like Marking my uncertainty on 2 ppm match explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises…
[2026 update] Clearance pathways and what renal impairment changes Replied, post #31 · Pharmacology › Pharmacokinetics · 6 Jun 2025 · 30 likes The bit of Clearance pathways that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread…
Pre-registering a personal experiment, seriously Replied, post #110 · Research Methods › N-of-1 designs · 3 Jun 2025 · 6 likes Post #108 and I disagree about the size of the effect, not about the direction. Pre-registering a personal experiment is worth one more sentence than it usually gets,…
A claim built entirely on a subgroup analysis Replied, post #59 · Evidence › Study critique · 27 May 2025 · 0 likes Surrogate endpoints are not automatically bad and their validity is compound-specific and population-specific. The question is whether this surrogate has been validated…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #94 · Compounds › Tirzepatide · 26 May 2025 · 5 likes Post #91 and I disagree about the size of the effect, not about the direction. Adding the boring version of tirzepatide in type 2 diabetes, because the interesting…
Second pass at: Designing a personal experiment that could change your mind Replied, post #44 · Research Methods › N-of-1 designs · 22 May 2025 · 20 likes Adding a note of thanks rather than an opinion. I did not know most of that.
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #107 · Compounds › Semaglutide · 7 May 2025 · 22 likes I read post #104 twice before replying, because I had assumed the opposite. Two sentences on SELECT and then I will stop, because the rest is speculation and the thread…
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence Replied, post #50 · Compounds › Secretagogues & GH axis · 26 Apr 2025 · 11 likes The most useful single question to ask about any compound in this family is what the published human evidence actually consists of. In several cases the honest answer…
Reading a trial's population section before its results — does this still hold? Replied, post #39 · Evidence › Trials · 25 Apr 2025 · 1 like Effect sizes in a trial population reflect adherence achieved under trial conditions, which is generally better than adherence outside them.
Scheduled maintenance and what will be unavailable Replied, post #111 · Meta › Announcements · 16 Apr 2025 · 29 likes The rare case here is the one that costs somebody a week, though, and the common case costs everyone ten seconds. I think the trade is clearly correct. Happy to be the…
Delayed gastric emptying and oral medication absorption: which drugs matter Replied, post #48 · Practice › Interactions · 15 Apr 2025 · 7 likes Marking my uncertainty on delayed gastric emptying and oral explicitly. I am confident about the direction, much less confident about the size, and not confident at all…
Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #127 · Access › International · 27 Mar 2025 · 1 like Post #123 put the caveat in the right place and I want to underline it. What I can speak to on Cross-border purchase within is narrow, so I will keep it narrow rather…
Talking to a therapist about this specifically — does this still hold? Replied, post #33 · Wellbeing › Mental health · 22 Mar 2025 · 2 likes Taking post #30 at face value and following it one step further. Maintenance brings a different set of psychological questions from loss, and the discussion here is…
UK access routes, dated and sourced — a second dataset Replied, post #50 · Regional › UK & Ireland · 14 Mar 2025 · 23 likes I read post #46 twice before replying, because I had assumed the opposite. Cost comparisons should state whether they include the consultation, the device, the needles…
[2026 update] Mood changes: monitoring, and when to involve a professional Replied, post #4 · Wellbeing › Mental health · 13 Mar 2025 · 2 likes Same experience here, different supplier, so it is at least not unique to one of them.
Domestic fridge temperature mapping: a cheap experiment — what changed since Replied, post #66 · Devices › Cold chain · 12 Mar 2025 · 16 likes A phase-change pack holds a defined temperature while it changes state and then behaves like anything else. A gel pack starts cold and warms continuously. They are…
Cost per milligram, computed honestly across formats — the long version Replied, post #25 · Access › Pricing · 5 Mar 2025 · 4 likes The most useful pricing posts here are the ones that show the arithmetic rather than the conclusion.
Consistent declarations and why they matter more than clever ones Replied, post #98 · Sourcing › Logistics · 27 Feb 2025 · 12 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
SNAC and the mechanism of oral peptide absorption — the long version Replied, post #30 · Compounds › Oral incretins · 16 Feb 2025 · 8 likes Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that…
Second pass at: A history of disordered eating: proceeding carefully Started this topic · Wellbeing › Mental health · 26 Jan 2025 · 1 like On the subject in the title: Second pass at: A history of disordered eating: proceeding carefully Working notes rather than a conclusion. Two things I would like…
Identical chromatograms across two different lots Replied, post #78 · Sourcing › Red flags · 18 Jan 2025 · 11 likes This settles it for me, at least until somebody posts a reason it should not.
Oxidation pathways for methionine and tryptophan Replied, post #52 · Analytics › Impurities & related substances · 30 Dec 2024 · 1 like My experience of oxidation pathways for methionine contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's…
Coming back to: Reading a meta-analysis you disagree with, fairly Replied, post #5 · Evidence › Meta-analyses · 11 Dec 2024 · 2 likes Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size or study quality. The choice affects the result and should be…
Why "any advice?" is the least effective ending for a post Replied, post #104 · Start Here › How to Ask · 4 Dec 2024 · 0 likes I read post #100 twice before replying, because I had assumed the opposite. Asking a follow-up: new topic or reply in the old one? If the answer depends on the previous…
Revisiting: Moderation log format change Replied, post #50 · Meta › Announcements · 1 Dec 2024 · 9 likes Reframing Moderation log format change slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen",…
Coming back to: Preparing for an appointment: one page, three questions Replied, post #96 · Clinical › Prescriber conversations · 9 Nov 2024 · 30 likes A question phrased as "what would you want to see before considering X" is answerable and is not a request for X. I am not the right person to answer the follow-up to…
A revision dispute resolved on the topic rather than in the history — a second dataset Replied, post #14 · Meta › Wiki maintenance · 21 Oct 2024 · 7 likes Confirming post #11 from a second method, which matters more than confirming it from a second person. Reporting an inconsistency between two maintained pages rather…
Second pass at: Hoarding and why it makes a shortage worse Replied, post #114 · Access › Shortages · 13 Oct 2024 · 15 likes Narrowing post #113, because the general version has more than one answer. Both are useful and different. The notice tells you the national position; the account tells…
Requesting a page: what makes a good request — what changed since Replied, post #79 · Documentation › Wiki requests · 11 Oct 2024 · 1 like Worth separating two things that post #75 runs together. Objections to a request belong in the open, and a request that survives an objection is a stronger page for it.…
Chronic kidney disease and the FLOW result — a second dataset Started this topic · Clinical › Comorbidities · 8 Oct 2024 · 11 likes Chronic kidney disease and the FLOW result — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset…
Promotion criteria, and the one that stops most nominations Replied, post #70 · Documentation › Doc review · 25 Sep 2024 · 28 likes Reviewing your own nomination is fine and is not sufficient. Somebody else has to read it for the process to mean anything. Same conclusion as the reply above, reached…
Second pass at: Sodium, potassium and magnesium when intake drops Replied, post #36 · Nutrition & Training › Hydration & electrolytes · 11 Aug 2024 · 1 like Helpful, and easy to find again, which is half of what a good reply is.
Guidelines revision: what changed and why Replied, post #46 · Meta › Announcements · 26 Jul 2024 · 5 likes The strongest argument against my own position on guidelines revision, stated as well as I can state it, since nobody else has yet.
Second pass at: Journal club: LEADER as the historical anchor Replied, post #60 · Evidence › Journal club · 24 Jul 2024 · 0 likes Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything…
Second pass at: Retatrutide dose escalation in the published trials Replied, post #16 · Compounds › Retatrutide · 16 Jul 2024 · 3 likes Practical answer on Retatrutide dose escalation, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether…
The mass-error checker and its intended scope Replied, post #3 · Data & Tools › Calculators · 19 May 2024 · 0 likes Mass-error checker is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says…